Dissemin is shutting down on January 1st, 2025

Published in

Springer, Cancer Chemotherapy and Pharmacology, 4(81), p. 647-658, 2018

DOI: 10.1007/s00280-018-3532-9

Links

Tools

Export citation

Search in Google Scholar

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death.